Real-World Outcomes of First-Line Nivolumab Monotherapy in Unfavorable Carcinoma of Unknown Primary: A Single-Center Retrospective Study
Medicine
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.